PhRMA Moves To Vanquish FTC Rule Targeting Drugmakers

Law360, New York (February 10, 2014, 5:29 PM EST) -- The Pharmaceutical Research and Manufacturers of America on Friday urged a D.C. federal judge to vacate a Federal Trade Commission rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under federal merger law, arguing that the agency lacks the authority to target specific sectors.

In a motion for summary judgment, the leading pharmaceutical trade group told the court that the November rule, which upped the reporting burden on its member companies, far exceeds the FTC's authority under the Hart-Scott-Rodino Act. That statute, according...
To view the full article, register now.